title: [A comparative study of antiarrhythmic and antihypoxic effects of magnesium sulfate, its prolonged form and blockers of calcium channels].
abstract: The aim of the study is the comparative study of treatment of heart and brain damages during the hypoxia with magnesium sulfate, verapamil, diltiazem. As a result of the experiment carried out on rats it was proved that magnesium sulfate and its prolonged form are not less active than the blockers of calcium channels, such as verapamil and diltiazem. It is possible to avoid lethal fibrillations caused by calcium chloride with the help of 25% magnesium sulfate solution (after intraperitoneal administration with the dose of 1000 mg/kg) in case we make arrythmogenic injection 5 minutes after inputting magnesium sulfate solution. During the arrhythmia induced by calcium chloride prolonged form of magnesium sulfate is also effective only if we inject the drug subcutaneous 30 minutes before the arrythmogenic injection. If the interval is 5 minutes lethal fibrillations cant be avoided as the release of magnesium ions from the drug form is slowed down. The drugs containing magnesium ions also displayed cytoprotective activity on the model of normobaric hypoxia. This was resulted in the increase of protective index. Neuroprotective action of magnesium ions (in the condition of hypoxia) is caused by maintaining homeostasis of calcium ions and by inhibition of exocytosis of neuromediators in the synaptic cleft. Thus, magnesium sulfate and its prolonged form can be used with the purpose of pharmacocorrection of heart and brain injuries during hypoxic conditions.
authors.affiliation: A. Tsereteli Kutaisi State University, Medical Faculty; Pharmaceutical company Legion "Provisus", Georgia.
authors.forename: M D
authors.initials: MD
authors.lastname: Samsonia
authors.forename: M A
authors.initials: MA
authors.lastname: Kandelaki
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D053840:Brugada Syndrome; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D000075224:Cardiac Conduction System Disease; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D006329:Heart Conduction System / Q000002:abnormalities; D000860:Hypoxia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D008297:Male; D010101:Oxygen Consumption; D051381:Rats; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D008278:Magnesium Sulfate